Solventum
SOLVENTUM CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$8.3B
Operating marginCalculated
26.2%
Net assets to total assetsCalculated
35.3%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
26.2%
Growth (revenue, 3-year average)
★★☆☆☆position among all companies
0.8%
Capital efficiency
★★★★★position among all companies
30.8%
Revenue and profit
Performance, financial position and capital allocation
Solventum
Recent performance trends
Solventum
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | Could not be retrieved | US$8.1 billion | US$8.2 billion | US$8.3 billion | US$8.3 billion |
| Operating income | Could not be retrieved | US$1.7 billion | US$1.7 billion | US$1.0 billion | US$2.2 billion |
| Net income | Could not be retrieved | US$1.3 billion | US$1.3 billion | US$0.5 billion | US$1.6 billion |
| Total assets | Could not be retrieved | Could not be retrieved | US$13.9 billion | US$14.5 billion | US$14.3 billion |
| Shareholders' equity | Could not be retrieved | US$11.7 billion | US$11.7 billion | US$3.0 billion | US$5.0 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | US$1.7 billion | US$1.9 billion | US$1.2 billion | US$0.4 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | US$-0.3 billion | US$-0.2 billion | US$-0.4 billion | US$2.8 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | US$-1.5 billion | US$-1.6 billion | US$-0.2 billion | US$-3.1 billion |
| Cash and cash equivalents | Could not be retrieved | Could not be retrieved | US$0.2 billion | US$0.8 billion | US$0.9 billion |
Revenue scale in the same industry
Solventum
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 10 companies
- 14 Intuitive SurgicalFY Dec 2025 US$10.1B
- 15 Rockwell AutomationFY Sep 2025 US$8.3B
- 16 SolventumThis companyFY Dec 2025 US$8.3B
- 17 Zimmer Biomet HoldingsFY Dec 2025 US$8.2B
- 18 Roper TechnologiesFY Dec 2025 US$7.9B
- … 25 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$2.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.5 billion | Consolidated | Disclosed |
| Net assets | US$5.0 billion | Consolidated | Disclosed |
| Net sales | US$8.3 billion | Consolidated | Disclosed |
| Operating income | US$2.2 billion | Consolidated | Disclosed |
| Net income | US$1.6 billion | Consolidated | Disclosed |
| Total assets | US$14.3 billion | Consolidated | Disclosed |
| Operating margin | 26.2% | Consolidated | Calculated |
| Net assets to total assets | 35.3% | Consolidated | Calculated |
| Net margin | 18.7% | Consolidated | Calculated |
| Return on equity | 30.8% | Consolidated | Calculated |